Literature DB >> 19361744

Busulfan in hematopoietic stem cell transplantation.

Stefan O Ciurea1, Borje S Andersson.   

Abstract

The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies. Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of generating therapeutic Bu levels, maximizing antileukemic efficacy. Bu-nucleoside analog-based conditioning chemotherapy, thus far represented by fludarabine (Flu), is becoming the conditioning chemotherapy regimen of choice for patients with acute myelogenous leukemia (AML) at many transplant centers. The use of busulfan Bu-based conditioning is extending rapidly also to hematopoietic stem cell transplantation (HSCT) for lymphoid malignancies, genetic diseases, and umbilical cord blood transplantation.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19361744      PMCID： PMC4261695          DOI： 10.1016/j.bbmt.2008.12.489

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  111 in total

1.  Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.

Authors:  Timothy Madden; Marcos de Lima; Neil Thapar; John Nguyen; Soonja Roberson; Daniel Couriel; Betty Pierre; Elizabeth J Shpall; Roy B Jones; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

2.  Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis.

Authors:  A R Hartman; S F Williams; J J Dillon
Journal:  Bone Marrow Transplant       Date:  1998-09       Impact factor: 5.483

3.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

4.  Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.

Authors:  Ashwin Kashyap; John Wingard; Pablo Cagnoni; Jones Roy; Stephan Tarantolo; Wendy Hu; Karl Blume; Joyce Niland; Joycelynne M Palmer; William Vaughan; Hugo Fernandez; Richard Champlin; Stephen Forman; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

5.  Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.

Authors:  Je-Hwan Lee; Seong-Jun Choi; Jung-Hee Lee; So-Eun Kim; Chan-Jeoung Park; Hyun-Sook Chi; Moo-Song Lee; Jung-Shin Lee; Woo-Kun Kim; Kyoo-Hyung Lee
Journal:  Ann Hematol       Date:  2004-12-04       Impact factor: 3.673

6.  Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.

Authors:  Borje S Andersson; Ashwin Kashyap; Victor Gian; John R Wingard; Hugo Fernandez; Pablo J Cagnoni; Roy B Jones; Stefano Tarantolo; Wendy W Hu; Karl G Blume; Stephen J Forman; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

7.  Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).

Authors:  A Devergie; D Blaise; M Attal; J D Tigaud; J P Jouet; J P Vernant; P Bordigoni; N Ifrah; C Dauriac; J Y Cahn
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

8.  High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.

Authors:  Michelle Geddes; S Bill Kangarloo; Farrukh Naveed; Diana Quinlan; M Ahsan Chaudhry; Douglas Stewart; M Lynn Savoie; Nizar J Bahlis; Christopher Brown; Jan Storek; Borje S Andersson; James A Russell
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

9.  Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia.

Authors:  P J Shaw; C E Scharping; R J Brian; J W Earl
Journal:  Blood       Date:  1994-10-01       Impact factor: 22.113

10.  Second cancer risk following Hodgkin's disease: a 20-year follow-up study.

Authors:  F E van Leeuwen; W J Klokman; A Hagenbeek; R Noyon; A W van den Belt-Dusebout; E H van Kerkhoff; P van Heerde; R Somers
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544
View more
  54 in total

1.  Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.

Authors:  Pei-Chih Lee; Rajesh Kakadiya; Tsann-Long Su; Te-Chang Lee
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

2.  Unrelated donor transplantation for acute myelogenous leukemia in first remission.

Authors:  Qaiser Bashir; Borje S Andersson; Marcelo Fernandez-Vina; Leandro de Padua Silva; Sergio Giralt; Alexandre Chiattone; Wei Wei; Manish Sharma; Paolo Anderlini; Elizabeth J Shpall; Uday Popat; Morgani Rodrigues; Richard E Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-16       Impact factor: 5.742

3.  Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.

Authors:  Sandi L Navarro; Timothy W Randolph; Laura M Shireman; Daniel Raftery; Jeannine S McCune
Journal:  J Proteome Res       Date:  2016-07-20       Impact factor: 4.466

4.  I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.

Authors:  H Yamamoto; N Uchida; N Matsuno; A Kon; A Nishida; H Ota; T Ikebe; N Nakano; K Ishiwata; H Araoka; S Takagi; M Tsuji; Y Asano-Mori; G Yamamoto; K Izutsu; K Masuoka; A Wake; A Yoneyama; S Makino; S Taniguchi
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

5.  Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

Authors:  Partow Kebriaei; Timothy Madden; Reza Kazerooni; Xuemei Wang; Peter F Thall; Celina Ledesma; Yago Nieto; Elizabeth J Shpall; Chitra Hosing; Muzaffar Qazilbash; Uday Popat; Issa Khouri; Richard E Champlin; Roy B Jones; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2010-07-30       Impact factor: 5.742

6.  Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.

Authors:  Lindsey R Lombardi; Christopher G Kanakry; Marianna Zahurak; Nadira Durakovic; Javier Bolaños-Meade; Yvette L Kasamon; Douglas E Gladstone; William Matsui; Ivan Borrello; Carol Ann Huff; Lode J Swinnen; Robert A Brodsky; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Leuk Lymphoma       Date:  2015-10-12

7.  High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma.

Authors:  Andrew A Lane; Steven L McAfee; Joanne Kennedy; Christine Dube; Eyal C Attar; Karen K Ballen; Bimalangshu R Dey; Thomas R Spitzer; Yi-Bin Chen
Journal:  Leuk Lymphoma       Date:  2011-05-25

Review 8.  Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.

Authors:  Benigno C Valdez; Borje S Andersson
Journal:  Environ Mol Mutagen       Date:  2010-07       Impact factor: 3.216

9.  Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide.

Authors:  Ji Hyun Lee; Jimin Choi; Kyung A Kwon; Suee Lee; Sung Yong Oh; Hyuk-Chan Kwon; Hyo-Jin Kim; Jin Yeong Han; Sung-Hyun Kim
Journal:  Korean J Hematol       Date:  2010-06-30

10.  Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice.

Authors:  Mohammad A Rafi; Han Zhi Rao; Paola Luzi; David A Wenger
Journal:  Mol Ther       Date:  2015-09-02       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.